JP5847156B2 - 肝細胞がんの処置方法 - Google Patents
肝細胞がんの処置方法 Download PDFInfo
- Publication number
- JP5847156B2 JP5847156B2 JP2013501523A JP2013501523A JP5847156B2 JP 5847156 B2 JP5847156 B2 JP 5847156B2 JP 2013501523 A JP2013501523 A JP 2013501523A JP 2013501523 A JP2013501523 A JP 2013501523A JP 5847156 B2 JP5847156 B2 JP 5847156B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hcc
- individual
- nanoparticles
- taxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31815310P | 2010-03-26 | 2010-03-26 | |
| US61/318,153 | 2010-03-26 | ||
| PCT/US2011/030037 WO2011119988A1 (en) | 2010-03-26 | 2011-03-25 | Methods of treatment of hepatocellular carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015091142A Division JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523656A JP2013523656A (ja) | 2013-06-17 |
| JP2013523656A5 JP2013523656A5 (Direct) | 2014-05-08 |
| JP5847156B2 true JP5847156B2 (ja) | 2016-01-20 |
Family
ID=44673662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501523A Active JP5847156B2 (ja) | 2010-03-26 | 2011-03-25 | 肝細胞がんの処置方法 |
| JP2015091142A Pending JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015091142A Pending JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9370494B2 (Direct) |
| EP (2) | EP2898884B1 (Direct) |
| JP (2) | JP5847156B2 (Direct) |
| KR (1) | KR101786142B1 (Direct) |
| CN (2) | CN103052385B (Direct) |
| AU (1) | AU2011230512B2 (Direct) |
| BR (1) | BR112012024349A2 (Direct) |
| CA (2) | CA2793536C (Direct) |
| DK (1) | DK2552438T3 (Direct) |
| ES (2) | ES2580135T3 (Direct) |
| HR (1) | HRP20160609T1 (Direct) |
| HU (1) | HUE027749T2 (Direct) |
| IL (2) | IL221886A (Direct) |
| LT (1) | LT2552438T (Direct) |
| MX (2) | MX346861B (Direct) |
| NZ (1) | NZ602382A (Direct) |
| PL (1) | PL2552438T3 (Direct) |
| PT (1) | PT2552438T (Direct) |
| TW (1) | TWI495467B (Direct) |
| WO (1) | WO2011119988A1 (Direct) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| MX383644B (es) | 2005-02-18 | 2025-03-14 | Abraxis Bioscience Llc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| EP2117520B1 (en) | 2006-12-14 | 2018-08-29 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| DK2155188T3 (da) * | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| EP3626233A1 (en) | 2009-04-15 | 2020-03-25 | Abraxis BioScience, LLC | Prion-free nanoparticle compositions and methods |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| KR20180050426A (ko) | 2010-03-29 | 2018-05-14 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2801645A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
| KR20140107417A (ko) | 2011-12-14 | 2014-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| WO2014159171A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| EP3003288A1 (en) | 2013-05-30 | 2016-04-13 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| US20150247204A1 (en) * | 2014-02-07 | 2015-09-03 | The General Hopital Corporation | Differential diagnosis of hepatic neoplasms |
| PT3223796T (pt) | 2014-11-25 | 2021-09-28 | Curadigm Sas | Composições farmacêuticas, preparação e suas utilizações |
| AR102778A1 (es) * | 2014-11-25 | 2017-03-22 | Nanobiotix | Composición farmacéutica, su preparación y sus usos |
| LT3229776T (lt) | 2014-11-25 | 2023-08-25 | Curadigm Sas | Farmacinė kompozicija, kurioje derinamos mažiausiai dvi skirtingos nanodalelės ir farmacinis mišinys, jos paruošimas ir vartojimas |
| LT3236934T (lt) | 2014-11-25 | 2024-08-26 | Curadigm Sas | Farmacinė kompozicija, preparatas ir jo panaudojimas |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| CN107708668A (zh) | 2015-05-28 | 2018-02-16 | 纳米生物技术公司 | 用作治疗性疫苗的纳米粒子 |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| EP3522887A4 (en) * | 2016-10-07 | 2020-06-10 | Abraxis BioScience, LLC | METHODS OF TREATING BILARIAN CANCER |
| WO2018081520A1 (en) | 2016-10-27 | 2018-05-03 | Zhuhai Beihai Biotech Co., Ltd. | Neutral ph compositions of docetaxel and human serum albumin |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| CN107828887A (zh) * | 2017-10-12 | 2018-03-23 | 上海市东方医院 | Stmn1基因的用途 |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| JP2024542042A (ja) * | 2021-10-26 | 2024-11-13 | リポジェムス・インターナショナル・エッセ・ピ・ア | 肝がん療法での薬物送達システムとしての微小断片化脂肪組織 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| ES2219646T5 (es) | 1993-02-22 | 2008-11-01 | Abraxis Bioscience, Inc. | Metodos para la administracion in vivo de compuestos biologicos y composiciones utiles para los mismos. |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| KR100789008B1 (ko) | 1997-06-27 | 2007-12-26 | 아브락시스 바이오사이언스 인크. | 신규 약물 제제 |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1171117A4 (en) | 1999-04-22 | 2002-08-07 | American Bioscience Inc | LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS |
| EP1178786A4 (en) | 1999-05-21 | 2006-03-01 | American Bioscience Inc | PHARMACOLOGICALLY ACTIVE PROTEIN STABILIZING AGENTS; METHODS OF MANUFACTURE AND METHODS OF USE |
| GB9920548D0 (en) | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| WO2004052401A2 (en) | 2002-12-09 | 2004-06-24 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| MX383644B (es) | 2005-02-18 | 2025-03-14 | Abraxis Bioscience Llc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
| BRPI0615265A8 (pt) * | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| JP5368093B2 (ja) | 2005-08-31 | 2013-12-18 | アブラクシス バイオサイエンス， エルエルシー | 増大した安定性を有する難水溶性薬剤の組成物および調製の方法 |
| JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| AU2006347740A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| EP2076599A2 (en) * | 2006-09-19 | 2009-07-08 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| EP2117520B1 (en) | 2006-12-14 | 2018-08-29 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| EP2131821B1 (en) | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| EP2146735B1 (en) | 2007-04-13 | 2012-06-20 | Abraxis BioScience, Inc. | Compositions comprising sparc polypeptides |
| CA2686736A1 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
| DK2155188T3 (da) | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
| US20120128732A1 (en) | 2008-12-11 | 2012-05-24 | Vuong Trieu | Combinations and modes of administration of therapeutic agents and combination therapy |
| JP5725563B2 (ja) | 2009-03-13 | 2015-05-27 | アブラクシス バイオサイエンス， エルエルシー | チオコルヒチン誘導体との組み合わせ療法 |
| MX2011010673A (es) | 2009-04-10 | 2012-02-21 | Abraxis Bioscience Llc | Formulaciones de nanoparticulas y usos de las mismas. |
| EP3626233A1 (en) | 2009-04-15 | 2020-03-25 | Abraxis BioScience, LLC | Prion-free nanoparticle compositions and methods |
| DK2470173T3 (en) | 2009-08-25 | 2016-06-06 | Abraxis Bioscience Llc | Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| KR20180050426A (ko) | 2010-03-29 | 2018-05-14 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| ES2639038T3 (es) | 2010-06-02 | 2017-10-25 | Abraxis Bioscience, Llc | Métodos para el tratamiento de cáncer de vejiga |
| CA2801645A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| RU2016103126A (ru) | 2010-06-07 | 2018-11-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы комбинированной терапии для лечения пролиферативных заболеваний |
| CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
| KR20140107417A (ko) | 2011-12-14 | 2014-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
-
2011
- 2011-03-25 ES ES11760333.2T patent/ES2580135T3/es active Active
- 2011-03-25 AU AU2011230512A patent/AU2011230512B2/en active Active
- 2011-03-25 EP EP14200645.1A patent/EP2898884B1/en active Active
- 2011-03-25 EP EP11760333.2A patent/EP2552438B1/en active Active
- 2011-03-25 LT LTEP11760333.2T patent/LT2552438T/lt unknown
- 2011-03-25 JP JP2013501523A patent/JP5847156B2/ja active Active
- 2011-03-25 DK DK11760333.2T patent/DK2552438T3/en active
- 2011-03-25 CN CN201180025949.1A patent/CN103052385B/zh active Active
- 2011-03-25 BR BR112012024349A patent/BR112012024349A2/pt not_active Application Discontinuation
- 2011-03-25 US US13/583,603 patent/US9370494B2/en active Active
- 2011-03-25 KR KR1020127027815A patent/KR101786142B1/ko active Active
- 2011-03-25 HU HUE11760333A patent/HUE027749T2/en unknown
- 2011-03-25 CA CA2793536A patent/CA2793536C/en active Active
- 2011-03-25 CA CA3051495A patent/CA3051495A1/en not_active Abandoned
- 2011-03-25 PL PL11760333.2T patent/PL2552438T3/pl unknown
- 2011-03-25 CN CN201510242264.2A patent/CN104784121A/zh active Pending
- 2011-03-25 MX MX2012010936A patent/MX346861B/es active IP Right Grant
- 2011-03-25 NZ NZ602382A patent/NZ602382A/en unknown
- 2011-03-25 PT PT117603332T patent/PT2552438T/pt unknown
- 2011-03-25 MX MX2016015444A patent/MX359413B/es unknown
- 2011-03-25 HR HRP20160609TT patent/HRP20160609T1/hr unknown
- 2011-03-25 WO PCT/US2011/030037 patent/WO2011119988A1/en not_active Ceased
- 2011-03-25 ES ES14200645.1T patent/ES2675212T3/es active Active
- 2011-03-28 TW TW100110703A patent/TWI495467B/zh active
-
2012
- 2012-09-11 IL IL221886A patent/IL221886A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/781,480 patent/US20140079787A1/en not_active Abandoned
-
2015
- 2015-04-28 JP JP2015091142A patent/JP2015134825A/ja active Pending
-
2016
- 2016-05-20 US US15/160,598 patent/US20160374952A1/en not_active Abandoned
- 2016-08-08 IL IL247171A patent/IL247171B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5847156B2 (ja) | 肝細胞がんの処置方法 | |
| JP6257324B2 (ja) | 膵臓がんの処置方法 | |
| JP6031437B2 (ja) | 増殖性疾患を処置するための組み合わせ療法 | |
| JP2013527232A (ja) | 膀胱がんの処置方法 | |
| JP2019529520A (ja) | 胆道がんを処置する方法 | |
| HK1212926B (en) | Methods of treatment of hepatocellular carcinoma | |
| HK1181665B (en) | Methods of treatment of hepatocellular carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140320 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140320 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150129 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151001 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151030 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151124 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5847156 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |